QM · rank #19 · 2026-10-20
ETON
NASDAQ · $1.58B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +202.62% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +36.0% |
| Profit margin Net profit margin, trailing 12 months. | +12.0% |
| Market cap (USD) Size filter: > $500M required. | $1.58B |
| Anchor (recent) Close on 2026-09-18 | $55.50 |
| Anchor (far) Close on 2025-09-19 | $18.34 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Eton Pharmaceuticals is a rare-disease commercialization platform with eleven commercial products built on exclusive licensed rights, orphan-drug positioning, and dedicated patient-access infrastructure rather than a broad proprietary patent portfolio.
Rationale
The 2.03 momentum score is directly supported by concrete fundamental catalysts — 99% YoY revenue growth, raised $145M guidance, IMPAVIDO launch, and LIBERVANT licensing — giving the quality-momentum signal genuine earnings-revision and price-trend backing rather than pure sentiment rotation.
Material risks
- 1LIBERVANT and IMPAVIDO are licensed, not owned, so a supplier dispute, renegotiation, or supply disruption could strip two of the platform's highest-visibility revenue contributors with limited internal recourse.
- 2LIBERVANT's contribution to the $145M guidance target remains contingent on final FDA approval and April 2027 launch execution, meaning a regulatory delay or rejection would force a guidance cut that directly breaks the momentum thesis.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.